|
Relmada Therapeutics Inc (NASDAQ: RLMD) |
|
Relmada Therapeutics Inc
RLMD's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Relmada Therapeutics Inc's sales fell
in III. Quarter 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.18 %
Relmada Therapeutics Inc net loss decreased from $-26 millions, to $-22 millions in III. Quarter 2024,
• More on RLMD's Growth
|
|
Relmada Therapeutics Inc realized a net loss in trailing twelve months.
Relmada Therapeutics Inc realized cash reduction of $ -0.82 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.
• More on RLMD's Valuation
|
|
|
|
|
Relmada Therapeutics Inc realized net loss in trailing twelve months.
Relmada Therapeutics Inc realized cash outflow of $ -0.82per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.45.
Relmada Therapeutics Inc Price to Book Ratio is at 0.19 lower than Industry Avg. of 82.94. and higher than S&P 500 Avg. of 0.02
• More on RLMD's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com